Icos Corporation

Eli Lilly and Company

Joshua O Odingo

Kerry W Fowler

Laurence Edward Burgess

Amy Oliver

Timothy J Martins

Stephen T Schlachter

Edward A Kesicki

John Joseph Gaudino

Bradley Jon Newhouse

Zachary S Jones

Danwen Huang

Stephen T Schlacter

Cynthia Darshini Jesudason

Gary G Deng

The invention provides certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula I, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder. 

Azetidinyloxyphenylpyrrolidine compounds

The invention provides certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula I wherein R is hydrogen or methyl, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder. 

Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.

Cyclic AMP-specific phosphodiesterase inhibitors

Cyclic AMP-specific phosphodie sterase inhibitors

Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.

Thiazole compounds as cyclic AMP-specific phosphodiesterase inhibitors and method of using the same

Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory disease and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.

Novel compounds that are potent and selective inhibitors of PIDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.

Growing community of inventors

Bothell, WA, United States of America

Joshua O Odingo